Massive presence of off-label medicines in Danish neonatal departments: A nationwide survey using national hospital purchase data
Research output: Contribution to journal › Journal article › Research › peer-review
Standard
Massive presence of off-label medicines in Danish neonatal departments : A nationwide survey using national hospital purchase data. / Gade, Christina; Trolle, Stine; Mørk, Mette Louise; Lewis, Anna; Andersen, Peter Fruergaard; Jacobsen, Thorkild; Andersen, Jon; Lausten-Thomsen, Ulrik.
In: Pharmacology Research and Perspectives, Vol. 11, No. 1, e01037, 2023.Research output: Contribution to journal › Journal article › Research › peer-review
Harvard
APA
Vancouver
Author
Bibtex
}
RIS
TY - JOUR
T1 - Massive presence of off-label medicines in Danish neonatal departments
T2 - A nationwide survey using national hospital purchase data
AU - Gade, Christina
AU - Trolle, Stine
AU - Mørk, Mette Louise
AU - Lewis, Anna
AU - Andersen, Peter Fruergaard
AU - Jacobsen, Thorkild
AU - Andersen, Jon
AU - Lausten-Thomsen, Ulrik
N1 - Publisher Copyright: © 2022 The Authors. Pharmacology Research & Perspectives published by British Pharmacological Society and American Society for Pharmacology and Experimental Therapeutics and John Wiley & Sons Ltd.
PY - 2023
Y1 - 2023
N2 - There is currently insufficient knowledge of gestational age dependent medicine disposition in neonates. Accordingly, the use of off-label medication, i.e., use of medicines outside its approved marketing authorization, is high in the neonatal departments. By using data from the Danish National Pharmaceutical Hospital Purchase Database, we identified the most commonly occurring medications and calculated the on/off-label ratios for premature and term neonates. Data was extracted on ATC level 5 and based on defined daily doses as per WHO. Data covered the 4 high-level NICUs and 10 of 13 of the intermediate/standard level Danish neonatal departments. Of the identified medication, 87% and 70% did not have approved marketing authorization for use in premature and full-term neonates, respectively. Furthermore, one-fifth of the top 100 medicines did not have a (Danish) marketing license. Overall, off-label medication was widespread covering virtually all ATC groups and no ATC group had an off-label level lower than 50% (range 50%–100%). Finally, in 21% of medications, additives from 8 different chemical groups with potential deleterious effects for neonates were identified. In conclusion, off-label medication in the Danish neonatal departments is widespread. The pharmaceutical industry is unlikely to solve this problem, and we may for a very long time be occasionally forced to use off-label medication. Practical solution must therefore come from multidisciplinary clinical and academic collaboration. Use of formulation list as guidance for prescriptions and NICU-friendly galenic formulations may mitigate the problem temporarily while waiting for definitive studies.
AB - There is currently insufficient knowledge of gestational age dependent medicine disposition in neonates. Accordingly, the use of off-label medication, i.e., use of medicines outside its approved marketing authorization, is high in the neonatal departments. By using data from the Danish National Pharmaceutical Hospital Purchase Database, we identified the most commonly occurring medications and calculated the on/off-label ratios for premature and term neonates. Data was extracted on ATC level 5 and based on defined daily doses as per WHO. Data covered the 4 high-level NICUs and 10 of 13 of the intermediate/standard level Danish neonatal departments. Of the identified medication, 87% and 70% did not have approved marketing authorization for use in premature and full-term neonates, respectively. Furthermore, one-fifth of the top 100 medicines did not have a (Danish) marketing license. Overall, off-label medication was widespread covering virtually all ATC groups and no ATC group had an off-label level lower than 50% (range 50%–100%). Finally, in 21% of medications, additives from 8 different chemical groups with potential deleterious effects for neonates were identified. In conclusion, off-label medication in the Danish neonatal departments is widespread. The pharmaceutical industry is unlikely to solve this problem, and we may for a very long time be occasionally forced to use off-label medication. Practical solution must therefore come from multidisciplinary clinical and academic collaboration. Use of formulation list as guidance for prescriptions and NICU-friendly galenic formulations may mitigate the problem temporarily while waiting for definitive studies.
KW - European Paediatric Regulation
KW - infant
KW - newborn
KW - NICU
KW - off-label medicines
KW - pharmacology
U2 - 10.1002/prp2.1037
DO - 10.1002/prp2.1037
M3 - Journal article
C2 - 36545691
AN - SCOPUS:85144596593
VL - 11
JO - Pharmacology Research & Perspectives
JF - Pharmacology Research & Perspectives
SN - 2052-1707
IS - 1
M1 - e01037
ER -
ID: 369079147